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Abstract
Introduction: Naturally occurring CD4+CD25+ regulatory T (Treg) cells are central to the maintenance of peripheral
tolerance. Impaired activity and/or a lower frequency of these cells lead to systemic lupus erythematosus (SLE).
Manipulating the number or activity of Treg cells is to be a promising strategy in treating it and other
autoimmune diseases. We have examined the effects of Y27, a novel derivative of 4-hydroxyquinoline-3-formamide,
on SLE-like symptoms in MRL/lpr autoimmune mice and BDF1 hybrid mice. Whether the beneficial effect of Y27
involves modulation of CD4+CD25+ Treg cells has also been investigated.
Methods: Female MRL/lpr mice that spontaneously develop lupus were treated orally by gavage with Y27 for 10
weeks, starting at 10 weeks of age. BDF1 mice developed a chronic graft-versus-host disease (GVHD) by two
weekly intravenous injections of parental female DBA/2 splenic lymphocytes, characterized by immunocomplex-
mediated glomerulonephritis resembling SLE. Y27 was administered to chronic GVHD mice for 12 weeks. Nephritic
symptoms were monitored and the percentage of CD4+CD25+FoxP3+ Treg peripheral blood leukocyte was
detected with mouse regulatory T cell staining kit by flowcytometry. Purified CD4+CD25+ Tregs were assessed for
immune suppressive activity using the mixed lymphocyte reaction.
Results: The life-span of MRL/lpr mice treated with Y27 for 10 weeks was significantly prolonged, proteinuria and
renal lesion severity were ameliorated, and blood urea nitrogen, triglyceride and serum anti-double-stranded DNA
antibodies were decreased. Similar results were found in chronic GVHD mice. Administration of Y27 had little
impact on percentage of the peripheral blood lymphocyte CD4+CD25+Foxp3+ Treg cells in both groups of mice. In
contrast, the suppressive capacity of CD4+CD25+ Treg cells in splenocytes was markedly augmented in Y27-treated
mice ex vivo.
Conclusions: Experimental evidence of the protect effects of Y27 against autoimmune nephritis has been shown.
The mechanism may involve enhancement of the suppressive capacity of CD4+CD25+ Treg cells.
Introduction
Systemic lupus erythematosus (SLE) is a disorder of
immune regulation characterized by the breakdown of
tolerance to self-nuclear, cytoplasmic and cell surface
molecules, and the production of autoantibodies to them.
Antibody- and immune complex-mediated inflammation
in SLE can lead to the development of glomerulonephritis,
dermatitis, serositis, and vasculitis [1]. The autoimmune
MRL/lpr mouse substrain spontaneously develops a severe
disease with many symptoms closely resembling human
SLE, that is, hypergammaglobulinemia, various autoanti-
bodies, and glomerulonephritis [2]. Murine chronic graft-
versus-host disease (GVHD) is a well-established lupus
model induced by transferring DBA/2 parental spleen cells
into (C57BL/6 × DBA/2) F1 (BDF1) mice. BDF1 mice
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develop a systemic autoimmune disorder resembling
human SLE, characterized by autoantibody production,
immunocomplex deposition and proteinuria [3-5]. In both
these models, an abnormal function of CD4+CD25+ regu-
latory T (Treg) cells may play a pivotal role.
Naturally arising CD4+ Treg cells expressing the IL-2
receptor a-chain (CD25) and the transcription factor fork-
head box P3 (FoxP3) represent a subset of thymus-derived
CD4+ T cells critical for the control of most immune
responses, including autoimmunity, transplantation toler-
ance, antitumor immunity and anti-infectious reactions
[6,7]. Treg cells fail to proliferate or secrete cytokines in
response to polyclonal or antigen-specific stimulation, but
can inhibit the proliferation and activation of conventional
CD4+CD25- effector T cells (Tconv) as well as CD8+
T cells [8]. The mechanisms by which Treg cells mediate
their suppressive effects have not been fully elucidated.
Treg cells suppress immune responses through contact-
dependent mechanisms and the production of soluble fac-
tors, including transforming growth factor b (TGF-b) and
IL-10 [9-13]. Quantitative and/or qualitative deficiencies
of Treg cells are considered responsible for a situation
where the sum of autoreactive effector T-cell responses
overwhelms the capacity of a weakened Treg compart-
ment, thereby triggering overt autoimmune disease [14].
Although there are some discrepant reports (possibly due
to variations in CD4+CD25+ T cell analysis), studies in
patients with SLE show that CD4+CD25+ Treg cell num-
bers are reduced and suppressive functions are compro-
mised when tested ex vivo [15]. Similar defects have been
found in lupus models. In lupus-prone MRL/lpr mice
developing a strong lupus disease, a reduced capacity to
suppress proliferation and especially, to inhibit interferon-
g (IFN-g) secretion by syngeneic effector CD4+CD25-
T cells occurs in vitro [16]. In BDF1 mice, infusion of puri-
fied Treg cells at the time of transplant can prevent the
development of lethal GVHD, whereas depletion makes
matters worse [17-19]. Therefore, expanding Treg or
enhancing Treg suppressive activity in vivo offers a pro-
mising strategy in lupus treatment.
Y27 is a novel 4-hydroxyquinoline-3-formamide deriva-
tive primarily derived from H1521, which could ameliorate
glomerular injury in the chronic GVHD murine model
[20] (Y27, Figure 1A; H1521, Figure 1B). Y27 and H1521
are both 4-hydroxy-7-methoxyquinoline-3-carboxamide.
Y27 differs from H1521 in that the N-substituent is tetra-
hydrofuran-2-methyl instead of 1-ethyl-tetrahydropyrrol-2-
methyl of H1521, that is, non-basic oxygen bioisosterically
replaces the basic nitrogen. Thus, Y27 merely has one
chiral center of 2-carbon with two enantiomers and this is
absent in the second chiral center of tertiary nitrogen of
H1521. This makes the Y27 product simple and in control
(H1521’s chemico-physical properties, including solubility
and pharmacokinetic characters, might change under dif-
ferent storage conditions and time).
Preliminary studies showed that Y27 could boost the sup-
pressive capacity of CD4+CD25+ Treg cells in C57BL/6
mice assessed in vitro by the mixed lymphocyte reaction
(MLR) (Figure 1C). We have focused on the protection
effect of Y27 against autoimmune nephritis in MRL/lpr
mice and BDF1 cGVHD mice. The influence of Y27 on
CD4+CD25+ Treg cells ex vivo was also followed. Y27 treat-
ment effectively ameliorated autoimmune syndromes in
MRL/lpr mice and BDF1 mice, which might be the conse-




Female MRL/Mp, MRL/lpr, CBA/Ca mice (6 to 8 weeks
old) were purchased from Shanghai SLAC Laboratory
Animal Co. Ltd (Shanghai, China). Female DBA/2, BDF1
and C57BL/6 mice (8 to 10 weeks old) were purchased
from Vitalriver Experimental Animal Center (Beijing,
China). Experiments were carried out in accordance with
the National Institutes of Health Guidelines for Care and
Use of Laboratory Animals, and were approved by the
Bioethics Committee of the Beijing Institute of Pharmacol-
ogy and Toxicology. All husbandry and experimental con-
tact with the mice was carried out under specific
pathogen-free conditions. The mice were allowed to accli-
matize in the facility for 1 week before experiments began.
Reagents
Horseradish peroxidase (HRP)-goat anti-mouse IgG was
purchased from Rockland Immunochemicals Inc, Gilberts-
ville, PA, USA. Anti-mouse IgG goat polyclonal antibody
was purchased from Santa Cruz Biotechnology Inc, Santa
Cruz, CA, USA. Calf thymus DNA and 3, 3’, 5, 5’-tetra-
methylbenzidine (TMB) were from Sigma-Aldrich, St.
Louis, MO, USA. RPMI 1640 medium and fetal bovine
serum (FBS) were purchased from GibcoBRL Life Technol-
ogies, Grand Island, NY, USA. Mouse CD4+CD25+ Treg
cell isolation kit was obtained from Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany. The mouse Treg cell staining
kit came from eBioscience, San Diego, CA USA, and con-
tained anti-mCD16/CD32, fluorescein isothiocyanate
(FITC)-conjugated anti-mCD4 (RM4-5), allophycocyanin
(APC)-conjugated anti-mCD25 (PC61.5), phycoerythrin
(PE)-conjugated FoxP3 (FJK-16s), with the required buffers.
Mouse TGF-b1, IL-2 and IFN-g ELISA kits were purchased
from Dakewe Biotech co., Ltd, Shenzhen, China.
MRL/lpr mice experiment protocol
Six-week-old MRL/lpr mice were monitored for the devel-
opment of nephritis by measuring urine protein weekly.
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Until 10 weeks of age, approximately 50% of the urine pro-
tein samples exceeded 2 mg/ml. To investigate the protec-
tive effects of Y27, MRL/lpr mice were randomly divided
into five groups (n = 6 or 10 mice per group) according to
body weight and urine protein level as follows: vehicle
control (saline), cyclophosphamide (CYC) 15 mg/kg/day,
or Y27 10, 20, 40 mg/kg/day by gavage. The experiment
was terminated after 10 weeks when all MRL/lpr mice
treated with vehicle control had developed 1+ proteinuria
(urine protein > 3 mg/ml). For mice that died before ter-
mination, the last known values for urinary protein were
carried forward. The experiments were repeated twice.
Induction of chronic GVHD and Y27 treatment
Chronic GVHD was induced in female BDF1 mice by
two weekly intravenous (iv) injections of 5 × 107 parental
female DBA/2 splenic lymphocytes. The BDF1 mice were
divided into five groups (n = 7 mice per group) according
to body weight and urine protein level, as follows: vehicle
control (saline) and Y27, 10, 20, 40 mg/kg/day. Age- and
sex-matched F1 mice serving as controls were injected iv
with the same volume of Hank’s buffer. Y27 was dis-
solved in saline and given by gavage once a day from 3
days after the last cell injection, continuing for 12 weeks.
Normal control and GVHD control mice received the
same dose of vehicle.
Proteinuria, blood urea nitrogen and triglyceride
Blood and urine samples were collected every other week
for assay. Mice were placed in metabolic cages for a 24-h
collection of urine, and urinary protein excretion was
determined using the Bradford assay. Urinary protein was
Figure 1 Structure of Y27 and its effect on CD4+CD25+ regulatory T (Treg) cells. (A) Structure of Y27. (B) Structure of H1521. (C) Y27
concentration-dependent enhancement of the suppressive capacity of CD4+CD25+ Treg cells in C57BL/6 mice in vitro. Suppressive activity of
CD4+CD25+ Treg cells was expressed as percent suppression calculated as following: 100 × (cpm (CD4+CD25- Tconv) - cpm (CD4+CD25- Tconv +
CD4+CD25+ Treg))/cpm (CD4+CD25- Tconv). Tconv, conventional CD4+CD25- effector T cells.
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scored according to the following criteria: 0 < 3 mg/ml; 1+,
3 mg/ml; 2+, 10 mg/ml; 3+, 30 mg/ml; and 4+, 100 mg/ml.
Serum blood urea nitrogen (BUN) and triglyceride levels
were measured with an automatic biochemical analyzer
(HITACHI, 7020).
Measurement of serum autoantibodies and
immunogIoblin
Anti-double-stranded DNA (anti-dsDNA) antibody and
immunoglobulin G (IgG) levels in serum were measured
using immunoassay as follows: microtiter plates were
coated with calf thymus DNA or goat anti-mouse IgG,
respectively. HRP-conjugated goat anti-mouse IgG (Santa
Cruz, CA, USA), 3,3’-5,5’ tetramethylbenzidine (TMB)
and H2O2 were added in that order. The reaction was
stopped with 2M H2SO4 and the plates were read at 450
nm in a Titertek Multiskan photometer (Netherlands).
Serum IgG1 and IgG2a levels were determined by sand-
wich ELISA. Briefly, microtiter plates were coated with
rabbit polyclonal antibody against mouse IgG (Santa Cruz,
CA, USA). Goat anti-mouse IgG1 or IgG2a were used for
primary Abs, with HRP-conjugated rat anti-goat IgG
(Santa Cruz, CA, USA) as the secondary Ab for ELISA.
Renal histopathology
Mice were sacrificed at the end of the study for histolo-
gical evaluation of the kidneys. The left kidney from
each mouse was removed, fixed in 4% formalin, and
embedded in paraffin. Five-micrometer sections were
stained with hematoxylin-eosin. An observer who was
blind to the source of each section scored glomeruli and
classified the lesion [21]. The following scale was
applied: 0, normal morphology; 1, moderate expansion
of the glomerular matrix without glomerulonephritis; 2,
mild glomerulonephritis with mesangial hypercellularity
and/or segmental necrosis; 3, severe glomerulonephritis
with extensive sclerosis and/or loop necrosis and/or cel-
lular crescent. A score was assigned to each of >100 glo-
meruli/ mouse, and the mean calculated for each group.
Flow cytometry
A CD4+CD25+FoxP3+ population assay was carried out
with mouse Treg cell staining kit. Briefly, murine periph-
eral blood lymphocytes were collected and blocked with
affinity purified anti-mCD16/CD32 (Fc block), stained
with FITC-conjugated anti-mCD4 (RM4-5), APC-conju-
gated anti-mCD25 (PC61.5), and PE-conjugated FoxP3
(FJK-16s). Samples were analyzed in a FACSCalibur sys-
tem with CellQuest software (BD, San Jose, CA, USA).
CD4+CD25- and CD4+CD25+ T cells preparation
Mice were sacrificed and the spleens removed aseptically.
A single splenocyte suspension was prepared, from which
cell debris and clumps were removed. Erythrocytes were
lysed with Tris-buffered ammonium chloride (0.155 M
NH4Cl and 16.5 mM Tris, pH 7.2). Mononuclear cells
were washed and resuspended in RPMI 1640 medium
containing 10% FBS. CD4+CD25- and CD4+CD25+ T cells
were isolated with mouse CD4+CD25+ Treg cell isolation
kit. Briefly, CD4+ T cells were firstly pre-enriched by
depleting unwanted cells using negative selection, and
CD25+ cells were isolated from the CD4+ cell population
by staining with PE-labeled anti-CD25 mAb followed by
incubation with magnetic-activated cell sorting (MACS)
anti-PE microbeads. CD4+CD25+ T cells were positively
selected on a MACS mini-separation magnetic column,
from which the flow-through fraction containing CD4
+CD25- T cells was collected. The purity of cell subsets
was > 90%, as determined by fluorescence activated cell
sorter (FACS) analysis.
Suppression assay
The suppressive capacity of CD4+CD25+ Treg cells was
assessed by the mixed lymphocyte reaction. CD4+CD25-
T cells were cultured (2 × 104 cells/well) in plates pre-
coated with anti-CD3 mAb (1 μg/ml) in the presence of
antigen-presenting cells (5 × 104/well T cell-depleted and
mitomycin C-treated splenic cells) [16], with or without
CD4+CD25+ T cells (104/well). Cultures were prepared in
complete RPMI 1640 medium supplemented with 10%
FBS. To measure proliferation, 3H-thymidine (0.5 μCi, spe-
cific activity 6.7 Ci/mmole) was added after 56 h and the
cells harvested 16 h later on a glass filter. The radioactivity
incorporated was determined with a Beta Scintillation
Counter (MicroBeta Trilux, Wellesley, MA, USA). Sup-
pressive activity of CD4+CD25+ Treg cells was expressed
as percent suppression calculated as following:
100×(cpm (CD4+CD25−Tconv) − cpm (CD4+CD25−Tconv + CD4+CD25+Treg))/cpm (CD4+CD25−Tconv) .
Cytokine analysis
The levels of TGF-b1 in the culture supernatants were
determined by ELISA, and the results were expressed as
the cytokine concentration pg/ml, with the detection
limit set at15 pg/ml.
Statistical analysis
Unless otherwise stated, data are expressed as mean ± stan-
dard error of the mean (SEM). One-way analysis of variance
(ANOVA) was used to assess significant differences
between groups. Dunnett’s multiple comparisons test was
used to test significant effects among multiple group means.
Results
Effect of Y27 on proteinuria, anti-dsDNA antibody, IgG
levels and kidney histological score in MRL/lpr mice
Generally, 50% mortality occurred at the 5th month of
the life-span in MRL/lpr mice [22]. Figure 2A shows
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Figure 2 Y27 treatment of lupus syndromes, and effects on serum antibody and renal histology in MRL/lpr mice. MRL/lpr mice
(10 weeks old) were treated with vehicle control (saline), cyclophosphamide (CYC; 15 mg/kg), or Y27 (10, 20 and 40 mg/kg) (n = 16 per group).
The experiment was terminated after 10 weeks of treatment when all MRL/lpr mice treated with vehicle control developed 1+ proteinuria (urine
protein > 3 mg/ml). (A) Effect of treatment on mortality over 10 weeks (analyzed by log rank test) and urinary protein levels at 10, 16 and
20 weeks of age. Each symbol represents one mouse. Bars show the mean of the group. (B) Effect of treatment on blood urea nitrogen and
triglyceride levels. (C) Anti-double-stranded DNA (anti-dsDNA) antibodies, IgG1and IgG2a levels after Y27 treatment. (D) Y27 attenuation of renal
histopathological changes in MRL/lpr mice (HE stain, 100×). For the blinded scoring of glomerular alterations see Materials and methods).*P <
0.05; **P < 0.01 versus MRL/Mp. #P < 0.05; ##P < 0.01 versus MRL/lpr.
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that 48.3% MRL/lpr mice died at the 20th week (10
weeks after Y27 administration), while Y27 significantly
increased mice survival. These experiments were
repeated twice, giving identical results, and thus the
data has been pooled (n = 16/group). At 10 weeks of
age, only half of MRL/lpr mice had low proteinuria
levels (Figure 2A). With aging, proteinuria in vehicle-
treated mice progressively increased, but the onset of
severe proteinuria was significantly delayed in both Y27-
and CYC-treated mice. At 16 weeks of age, all mice in
the vehicle-treated group developed 1+ proteinuria com-
pared with two of sixteen mice in the high dose Y27-
treated group. At 20 weeks of age, five mice developed
2+ proteinuria, and other mice developed 1+ proteinuria
in the vehicle-treated group compared with one mouse
that developed 2+ proteinuria, and with two mice that
developed 1+ proteinuria after high dose Y27 treatment.
Except for the three mice that developed proteinuria as
mentioned, two mice died during the experiment, while
the remaining eleven in this group did not develop pro-
teinuria (Figure 2A). At the end of treatment, mice also
had significantly elevated serum BUN and triglyceride
from 18 weeks of age, while treatment with 40 mg/kg
Y27 significantly improved the situation (Figure 2B).
The presence of high avidity IgG autoantibodies to
dsDNA tends to be correlated with SLE disease activity.
The levels of serum anti-dsDNA antibody in our investiga-
tion significantly increased from 16 weeks of age in MRL/
lpr mice, remaining high until the end of the experiment.
Y27, given at 40 mg/kg, decreased serum anti-dsDNA
antibody level (Figure 2C). Moreover, as an important
immunological parameter, serum IgG1 and IgG2a levels
were markedly elevated in MRL/lpr mice. Y27 significantly
decreased IgG1 and IgG2a levels at both 20 and 40 mg/kg
(Figure 2C).
Proteinuria is the direct result of renal damage, the
severity being assessed histologically by a board-certified
pathologist using the scoring method outlined in the
Methods and Material section, as described by Senuma
et al. [21]. The mice remaining at the end of the experi-
ment were analyzed for the presence and extent of glo-
merulonephritis by conventional histology. Figure 3B
shows the histological score of MRL/lpr mice as > 3,
implying that extensive sclerosis and/or loop necrosis and/
or cellular crescent appeared in almost every glomerulus.
Y27 treatment, notably a high dose regimen, reduced the
severity of the renal histopathology as compared to vehi-
cle-treated mice (approximately 1.5- to 1.3-fold decrease
in average score compared to vehicle, Figure 3E).
Effect of Y27 on the quantity and suppressive capacity of
CD4+CD25+FoxP3+ Treg cells in MRL/lpr mice
We had noted from earlier studies that Y27 could
enhance the suppressive capacity of CD4+CD25+ Treg
cells in C57BL/6 mice assessed by MLR without aug-
menting the CD4+CD25+FoxP3+ population (Figure 1C).
Here, we first examined the percentage of Treg cells in
MRL/lpr mice by flow cytometry. As before, MRL/lpr
mice had a normal percentage of CD4+CD25+FoxP3+
T cells in the peripheral blood (5.59% versus 5.73%,
Figure 3A, 3B). CYC treatment significantly augmented
the Treg population (8.49%, P < 0.01), but simulta-
neously reduced peripheral blood leukocyte count (data
not shown). Thus, the number of CD4+CD25+FoxP3+ T
cells remained unaltered in CYC-treated mice. Unlike
CYC, Y27 treatment affected neither the percentage of
Treg cells (5.14%, 5.07%, 5.66%, Figure 3A, 3B) nor per-
ipheral blood leukocyte count (data not shown). Like-
wise, the quantity of CD4+CD25+FoxP3+ T cells was
unchanged in either of the Y27-treated mice.
Regarding quantitative analysis of Treg cells, we have
investigated the regulatory properties of CD4+CD25+ Treg
by incubating CD4+CD25- effector T cells, stimulated
with both anti-CD3 mAb and haplotype-matched antigen
presenting cells, with CD4+CD25+ T cells (ratio 2:1).
CD4+CD25+ T cells purified fromMRL/lprmice displayed a
non-proliferation phenotype when stimulated by anti-CD3
mAb and autologous antigen presenting cells (Figure 3C).
Under these activation conditions, a reduced capacity of
MRL/lpr Treg cells to inhibit the proliferation of syngeneic
effector T cells was seen compared with co-cultures with
MRL/Mp Treg cells and effector T cells (8.3% versus 17.3%,
P < 0.05). CYC treatment seemed to reduce further the
suppressive capacity of Treg cells, which affected CD4+
CD25- effector T cell proliferation more markedly than
CD4+CD25+ T cells. However, an apparent recuperative
capacity of Treg cells to inhibit the proliferation of effector
T cells was seen in Y27-treated mice. Notably with 20 and
40 mg/kg Y27, the suppressive capacity of MRL/lpr Treg
cells was restored to syngeneic co-cultures with CBA/Ca
Treg cells and effector T cells (approximately 35%).
Effect of Y27 on cytokine TGF-b1 and IL-10 production
ex vivo in MRL/lpr mice
To examine the possible path by which Y27 enhances the
suppressive capacity of CD4+CD25+ Treg cells, the key
cytokines TGF-b1 and IL-10 ex vivo were detected in
MRL/lpr mice, since they play an important role in Treg
inhibition. TGF-b1 and IL-10 levels in the supernatants
of CD4+CD25+ T cells stimulated with anti-CD3 mAb
were only mildly decreased in MRL/lpr mice compared
with MRL/Mp mice, whereas CYC and Y27 significantly
increased TGF-b1 and IL-10 production (Figure 4).
Effect of Y27 on proteinuria, anti-dsDNA antibody, IgG
levels and kidney histological score in BDF1 mice
In BDF1 mice, 1+ proteinuria occurred from the 8th
week after BDF1 recipients were injected with DBA/2
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lymphocytes (Figure 5A). At the 12th week, all the mice
treated with vehicle developed proteinuria, whereas
onset was significantly postponed in Y27-treated mice
(Figure 5A). In the Y27 40 mg/kg group, none of the
mice developed proteinuria. BUN and triglyceride levels
were also significantly increased in GVHD mice at 8 to
12 weeks after cell transfer, whereas Y27 treatment low-
ered them (Figure 5B).
In BDF1 mice, serum anti-dsDNA antibody was mark-
edly elevated from 10 weeks after the second cell injection,
which was sustained until the 12th week. Y27 inhibited
the rise of serum anti-dsDNA antibody, the effect being
statistically significant at 40 mg/kg compared with the
control group (Figure 5C). Among serum IgG subtypes,
IgG1 was preferentially elevated from 6 weeks after sensiti-
zation, whereas IgG2a was barely changed in chronic
GVHD controls. Y27 significantly decreased IgG1 level at
40 mg/kg, with little influence on IgG2a level (Figure 5C).
Chronic GVHD resulted in the development of immu-
nocomplex-mediated glomerulonephritis, the pathological
Figure 3 Y27 treatment influence on the percentage of CD4+CD25+FoxP3+ regulatory T (Treg) cells in peripheral blood, and the
suppressive capacity of CD4+CD25+ Treg cells in MRL/lpr mice. MRL/lpr mice (10 weeks old) were treated with vehicle control (saline),
cyclophosphamide (CYC; 15 mg/kg), or Y27 (10, 20 and 40 mg/kg) for 10 weeks (n = 7 to 10 per group). (A) and (B) The percentage of peripheral
blood CD4+CD25+FoxP3+ Treg cells is unaltered in Y27-treated MRL/lpr mice. (C) Suppressive capacity of CD4+CD25+ Treg cells is significantly
increased after Y27 treatment Percent suppression = 100 × (cpm (CD4+CD25- Tconv) - cpm (CD4+CD25- Tconv + CD4+CD25+ Treg))/cpm (CD4+CD25-
Tconv). Results represent mean ± standard error of the mean (SEM). ##P < 0.01 versus MRL/lpr. Tconv, conventional CD4+CD25- effector T cells.
Xiao et al. Arthritis Research & Therapy 2012, 14:R235
http://arthritis-research.com/content/14/6/R235
Page 7 of 13
changes being similar to those in lupus nephritis; the
changes were noted about the 12th week after GVHD
induction. The renal histopathology score was significantly
higher in the GVHD model group (2.8 ± 0.2) than in the
control group. Y27 treatment at 10, 20, and 40 mg/kg low-
ered the scores to 2.4 ± 0.3, 2.2 ± 0.4 and 1.9 ± 0.3, respec-
tively (Figure 5D).
Effect of Y27 on the quantity and suppressive capacity of
CD4+CD25+FoxP3+ Treg cells in BDF1 mice
In BDF1 mice, CD4+CD25+FoxP3+ Treg cells represented
1.72% of peripheral blood leukocytes in the control
group, whereas in sensitized BDF1 mice there was a sig-
nificant decrease (0.75%) (Figure 6A, B). This decrease
was also partly compromised by increase in the periph-
eral blood leukocyte count (data not shown). Y27 treat-
ment did not influence the CD4+CD25+FoxP3+ Treg
population at any of the three doses (0.80%, 0.82%, 0.77%
respectively, Figure 6A, B), nor did it influence the leuko-
cyte count in peripheral blood compared with cGVHD
mice (data not shown).
An analogous assessment of the suppressive properties
of CD4+CD25+ Treg cells was also conducted in BDF1
mice. Upon activation with anti-CD3 mAb and autologous
antigen presenting cells, there was no clear difference in
the suppressive properties between the control and the
GVHD groups (40.3% versus 42.4%, Figure 6C). However,
CD4+CD25+ Treg cells from Y27-treated GVHD mice had
enhanced suppressive activity, particularly at 20 and
40 mg/kg (71.24%, P < 0.01; 59.58%, P < 0.05).
Discussion
The novel compound Y27 showed potent immunosup-
pressive activity both in vitro and in vivo, including
enhanced suppressive capacity of purified CD4+CD25+
Treg cells in preliminary screenings. In the present study,
our results indicate that Y27 treatment strongly prevented
the development of proteinuria and nephritis symptoms,
decreased serum autoantibody production, ameliorated
lethal renal injury, and consequently prolonged the life-
span of both lupus-prone types of mice. The therapeutic
effects of Y27 may, at least partially, contribute to the
restoration of the suppressive activity of Treg cells.
Autoimmunity can result from a loss of regulation of
autoreactive T cells. CD4+CD25+ Treg cells are of para-
mount importance in the maintenance of peripheral
self-tolerance and avoidance of autoimmunity [23,24].
However, defects in the number and function of Treg
cells, as well as a resistance of effector T cells to Treg
cell-mediated suppression, could each contribute to fail-
ure in T cell regulation [15,16]. Each of these defects
appears to contribute to the development of autoimmu-
nity in several models. The underlying mechanisms by
which these defects in regulation occur in lupus models
have also been investigated. A deficiency of Treg cell
numbers in two murine models, (NZB × NZW) F1 and
(SWR × NZB) F1 has been noted [22]. However, MRL/
lpr lupus mice, in which a fatal immune complex glo-
merulonephritis develops, are not deficient in CD4+
CD25+FoxP3+ Treg cells compared with non-autoim-
mune mice [16]. Consistent with this report, MRL/lpr
mice had a normal percentage of CD4+CD25+FoxP3+
T cells in the peripheral blood in our study. The che-
motherapeutic alkylating agent, CYC, is widely used to
treat autoimmune disorders with a dose-dependent
bimodal effect on the immune system. CYC reduces the
number of Treg cells in healthy mice; the changes found
by others were minor and short-lived [25,26]. Our data
indicate that the absolute number of CD4+CD25+
FoxP3+ T cells was unaltered after CYC treatment,
Figure 4 Y27 treatment promotion of transforming growth factor (TGF)-b1 and interleukin (IL)-10 secretion by purified CD4+CD25+
T regulatory (Treg) cells in MRL/lpr mice. MRL/lpr mice (10 weeks old) were treated with vehicle control (saline), cyclophosphamide (CYC; 15 mg/kg),
or Y27 (10, 20 and 40 mg/kg) for 10 weeks. (n = 4). Results represent mean ± standard error of the mean (SEM). ##P < 0.01 versus MRL/lpr.
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Y27 40 mg/kg Y27 10 mg/kg Y27 20 mg/kg 
control GVHD 
Figure 5 Y27 treatment amelioration of lupus syndromes, and effects on serum antibody and renal histology in BDF1 mice. Chronic
graft-versus-host disease (GVHD) was induced in recipient BDF1 mice by two intravenous injections of donor parental DBA/2 mice lymphocytes.
Y27 (10, 20 and 40 mg/kg) was given from 3 days after the last cell injection, the control and model mice being given the same dose of vehicle
(n = 7 per group). (A) Effect of treatment on mortality over 10 weeks (analyzed by log rank test) and urinary protein levels at the end of the
experiment. Each symbol represents one mouse. Bars show the mean of the group. (B) Effect of treatment on blood urea nitrogen and
triglyceride levels. (C) Anti-dsDNA antibodies and IgG1 levels decreased after Y27 treatment. (D) Y27 attenuated renal histopathology change in
BDF1 mice (HE stain, 100×). Blinded scoring of glomerular alterations was done as indicated in Materials and methods. Bars show the mean ±
standard error of the mean (SEM). **P < 0.01 versus control; #P < 0.05, ##P < 0.01 versus GVHD.
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although the percentage Treg cells in the CD4+ popula-
tion increased. This might be due to leucopenia caused
by CYC. Y27 did not affect either the percentage of
CD4+CD25+FoxP3+ T cells or the peripheral blood leu-
kocyte count.
In addition to a numerical deficiency of CD4+CD25+
Treg cells contributing to the pathogenesis of SLE, func-
tional abnormalities of Treg cells may also exist. While
MRL/Mp CD4+CD25+ Treg cells show only subtle
abnormalities of regulatory function, MRL/lpr CD4+
CD25+ Treg cells have a distinctly reduced capacity to
inhibit the proliferation of effector T cells [16]. In con-
cordance with these results, we have demonstrated that a
more severe decrease in Treg cell function can be seen in
MRL/lpr mice compared to MRL/Mp mice. CYC treat-
ment leads to a further decrease in Treg cell function
Figure 6 Y27 treatment effect on the percentage of CD4+CD25+FoxP3+ regulatory T (Treg) cells in peripheral blood, and the
suppressive capacity of CD4+CD25+ Treg cells in BDF1 mice. Chronic graft-versus-host disease (GVHD) was induced in recipient BDF1 mice
by two intravenous injections of donor parental DBA/2 mice lymphocytes. Y27 (10, 20 and 40 mg/kg) was given from 3 days after the last cell
injection. The control and model mice received the same dose of vehicle (n = 7 per group). (A) and (B) Y27 treatment affect the percentage of
peripheral blood CD4+CD25+FoxP3+ Treg cells. (C) Effect of Y27 treatment on the suppressive capacity of CD4+CD25+ Treg cells. Percent
suppression = 100 × (cpm (CD4+CD25- Tconv) - cpm (CD4+CD25- Tconv + CD4+CD25+ Treg))/cpm (CD4+CD25- Tconv). Results represent mean ±
standard error of the mean (SEM). **P < 0.01 versus control. Tconv, conventional CD4+CD25- effector T cells.
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[25,27]. However, Y27 increases the suppressive capabil-
ity of Treg cells quite remarkably. It remains difficult to
determine whether the increase in Treg cell inhibition in
MRL/lpr mice is due to an enhanced competence in the
CD4+CD25+ T cell population or sensitization of respon-
der CD4+CD25- T cells themselves to be suppressed. To
clarify this issue, a series of crossover experiments will be
necessary.
Inadequate soluble cytokines TGF-b and IL-10 mostly
contribute to defective Treg cell function [9-11]. The sup-
pressive effects of TGF-b can be transmitted to effector T
cells through its soluble forms, or its direct contact with
Tregs, which display TGF-b on their surface [28]. When
cell-to-cell contact takes place, TGF-b molecules on the
surface of Tregs aggregate, and this is triggered by signals
emanating from cytolytic T-lymphocyte-associated anti-
gen-4 (CTLA-4) [28]. IL-10 is another important Treg-
associated cytokine that might regulate the pathogenesis
of SLE. It impedes the activation/expansion of autoreactive
lymphocytes by preventing the activation of antigen pre-
senting cells and downregulating the expression of co-
stimulatory molecules [29]. Furthermore, IL-10 may play a
role in Treg commitment and function [29]. In our study,
an increase of both TGF-b and IL-10 was found in the
supernatants of Treg cells after Y27 treatment. We specu-
late that elevated TGF-b1 and IL-10 production by Treg
cells contributes, at least partially, to enhanced suppressive
capacity of Treg cells facilitated by Y27.
In another lupus-prone BDF1 mouse, immune toler-
ance to self-antigens may be defective, while onset of
chronic GVHD gives rise to autoimmune manifestations
in the disorder. Recent attention has focused on CD4
+CD25+ Treg cells and their relationship to chronic
GVHD [30]. Treg number measured by CD4+CD25
+FoxP3+ staining has been found to be decreased in
patients with chronic GVHD [31-33]. Moreover, Treg
number was found to return to normal in patients with
resolved chronic GVHD. Our chronic GVHD mice
showed a robust decrease in the percentage of CD4
+CD25+FoxP3+ T cells, which was compromised by an
expanded T cell population. When purified, these Treg
cells had considerable suppressive ability in vitro. Unlike
current immunosuppressants, such as sirolimus, which
exert their effect through expansion of Treg [34], Y27
had little effect on Treg number. However, Y27 greatly
increased the suppressive capability of Treg cells, and the
mechanism(s) involved are now under investigation.
A novel oral quinoline-3-carboxamide derivative, laqui-
nimod, is being assessed in the treatment of relapsing-
remitting (RR) multiple sclerosis (MS) and other autoim-
mune diseases [35-37]. Laquinimod is structurally related
to roquinimex (linomide), which has been demonstrated
to have efficacy in MS [38], although its development was
halted after unexpected serious adverse events in a phase
III trial [39]. However, Laquinimod has since shown
efficacy in phase II and phase III MS clinical trials without
evident immunosuppression or significant toxicity
[35,36,40]. The precise mechanisms of action of laquini-
mod have yet to be elucidated; however, current studies in
the MS model, experimental autoimmune encephalomye-
litis (EAE), indicate that laquinimod can suppress immune
cell migration and expression of inflammatory cytokines,
including IFN-g, TNF-a, IL-13, and IL-17 [41]. In addi-
tion, laquinimod can increase CD4+CD25+Foxp3-expres-
sing Treg cells in spleens of C57BL/6 mice immunized
with MOG p35-55. Moreover, Foxp3-expression was
induced by laquinimod by direct action on antigen-pre-
senting cells function. When purified laquinimod-treated
splenic CD11b+CD11c- cells were used as antigen-present-
ing cells in co-culture with naïve MOG p35-55-specific
T cells, Foxp3-expressing CD4+ T cells were significantly
elevated compared with the vehicle control [42]. As stu-
dies of the use of laquinimod in lupus are few, we do not
know whether it could affect Treg and antigen-presenting
cells in lupus models. Sharing some structural similarity
with laquinimod, Y27 might promote the suppression
capacity of Y27 through altered antigen-presenting cell
function, but this is a hypothesis that needs verification.
Conclusions
In conclusion, our results provide direct evidence of the
protective effects of the novel 4-hydroxyquinoline-3-for-
mamide derivative, Y27, against two murine SLE-like dis-
ease models. In both spontaneous lupus-prone MRL/lpr
mice and sensitized BDF1 mice, Y27 showed potent dis-
ease-modifying activity. The mechanism might involve
enhancement of the suppressive capacity of CD4+CD25+
Treg cells.
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